Non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration
Conditions
Brief summary
Comparision between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF) (Baseline to last on-treatment visit)
Detailed description
Comparision between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) (Baseline to last on-treatment visit), Comparision between groups of annual rate of change in mean sensitivity of grid points using mesopic microperimetry (MP) (Baseline to last on-treatment visit)
Interventions
DRUGGAL-101 ophtalmic solution matching placebo. It contains the excipients as GAL-101 ophtalmic solution plus Sodium Chloride instead of the API
DRUGwhich allows to achieve the same osmolarity as GAL-101 ophtalmic solution
DRUGGAL-101 salt
Sponsors
Galimedix Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparision between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF) (Baseline to last on-treatment visit) | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparision between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) (Baseline to last on-treatment visit), Comparision between groups of annual rate of change in mean sensitivity of grid points using mesopic microperimetry (MP) (Baseline to last on-treatment visit) | — |
Countries
France, Germany, Ireland, Italy
Outcome results
None listed